17-11-5　ⓔ文献

  1. 朝倉英策：播種性血管内凝固症候群 (DIC)．臨床に直結する血栓止血学 改訂2版 (朝倉英策編)，中外医学社，2018; 286–299.

  2. Levi M, Ten Cate H: Disseminated intravascular coagulation. N Engl J Med, 1999; 341: 586–592.

  3. Gando S, Levi M, et al: Disseminated intravascular coagulation. Nat Rev Dis Primers, 2016; 2: 16037.

  4. Toh CH, Alhamdi Y, et al: Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation. Ann Lab Med, 2016; 36: 505–512.

  5. Asakura H: Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care, 2014; 2: 20.

  6. Asakura H, Takahashi H, et al: DIC subcommittee of the Japanese Society on thrombosis and hemostasis: proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J, 2016; 14: 42.

  7. Laursen MA, Larsen JB, et al: Platelet function in disseminated intravascular coagulation: a systematic review. Platelets, 2018; 29: 238–248.

  8. Kander T, Larsson A, et al: Assessment of haemostasis in disseminated intravascular coagulation by use of point–of–care assays and routine coagulation tests, in critically Ill patients; a prospective observational study. PLoS One, 2016; 11: e0151202.

  9. 日本血栓止血学会：診療ガイドライン DIC診断基準2017年度版．http://www.jsth.org/guideline/dic診断基準2017年度版/

  10. Hayashi T, Morishita E, et al: Expression of annexin II in experimental abdominal aortic aneurysms. Int J Hematol, 2009; 90: 336–342.

  11. Hayashi T, Morishita E, et al: Expression of annexin II in human atherosclerotic abdominal aortic aneurysms. Thromb Res, 2008; 123: 274–280.

  12. Kadohira Y, Asakura H, et al: Aortic aneurysm–associated disseminated intravascular coagulation that responded well to a switch from warfarin to rivaroxaban. Intern Med, 2017; 56: 2913–2917.

  13. Hayashi T, Asakura H, et al: Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm: a case report. Ann Intern Med, 2014; 161: 158–159.

  14. Wada H, Matsumoto T, et al: Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J, 2018; 16: 14.

  15. Schwameis M, Schörgenhofer C, et al: VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost, 2015; 113: 708–718.

  16. Kurosawa S, Stearns–Kurosawa DJ: Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care, 2014; 2: 65.

  17. Scully M, Cataland S, et al: Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.J Thromb Haemost, 2017; 15: 312–322.

  18. Kurita N, Sakamoto T, et al: The prognosis of disseminated intravascular coagulation associated with hematologic malignancy and its response to recombinant human thrombomodulin. Thromb Res, 2019; 173: 57–64.

  19. Yatabe T, Inoue S, et al: The anticoagulant treatment for sepsis induced disseminated intravascular coagulation; network meta–analysis. Thromb Res, 2018; 171: 136–142.

  20. Ouchi K, Takahashi S, et al: Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors. Int J Clin Oncol, 2018; 23: 790–798.

  21. Umemura Y, Yamakawa K: Optimal patient selection for anticoagulant therapy in sepsis: an evidence–based proposal from Japan. J Thromb Haemost, 2018; 16: 462–464.

  22. Kojima S, Nishioka C, et al: In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome. Leuk Res, 2017; 63: 1–9.

  23. Ontachi Y, Asakura H, et al: Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. Circ J, 2005; 69: 1150–1153.

  24. Ontachi Y, Asakura H, et al: Kasabach–Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid. Haematologica, 2005; 90: ECR29.

  25. Koseki M, Asada N, et al: Successful combined use of tranexamic acid and unfractionated heparin for life–threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Int J Hematol, 2007; 86: 403–406.